Glycinamide Ribonucleotide Formyltransferase Inhibitors
6 drugsAbout Glycinamide Ribonucleotide Formyltransferase
Glycinamide Ribonucleotide Formyltransferase is an enzyme essential for purine biosynthesis, catalyzing a key step in inosine monophosphate (IMP) formation. By enabling the production of adenosine and guanosine nucleotides, it supports DNA and RNA synthesis. Inhibiting this enzyme disrupts nucleotide synthesis, hindering cell growth and proliferation.
As a critical enzyme for nucleotide production, Glycinamide Ribonucleotide Formyltransferase is a therapeutic target in rapidly dividing cells like cancerous tumors. Currently, there is no genetic evidence directly linking this target to specific diseases, but its role in nucleotide metabolism makes it compelling.
Glycinamide Ribonucleotide Formyltransferase is targeted by six FDA-approved small molecule drugs, including PEMETREXED DISODIUM (ALIMTA), AXTLE, PEMETREXED, and PEMFEXY, all for oncology indications. These drugs are marketed by six companies including QILU PHARM HAINAN, AVYXA HOLDINGS, SHILPA, EAGLE PHARMS, and Eli Lilly.
Top Glycinamide Ribonucleotide Formyltransferase Drugs
Six companies have approved drugs targeting Glycinamide Ribonucleotide Formyltransferase, indicating a moderately competitive landscape.
Consider partnerships or acquisitions to consolidate market share and reduce competitive pressure.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| PEMETREXED DISODIUM | Apotex | 2022 | 2 |
| PEMETREXED | SHILPA | 2020 | 2 |
| PEMETREXED FOR INJECTION | Dr. Reddy's | - | - |
Glycinamide Ribonucleotide Formyltransferase Drug Modality Landscape
Modalities
Routes of Administration
Glycinamide Ribonucleotide Formyltransferase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like PROTACs or biologics to differentiate from existing therapies.
Glycinamide Ribonucleotide Formyltransferase Clinical Trials 758 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Glycinamide Ribonucleotide Formyltransferase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 208 | 83 | 41 | 83 | 67% |
| Phase 2 | 344 | 103 | 81 | 158 | 56% |
| Phase 3 | 193 | 63 | 28 | 102 | 69% |
| Phase 4 | 13 | 6 | 3 | 4 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Glycinamide Ribonucleotide Formyltransferase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Glycinamide Ribonucleotide Formyltransferase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Glycinamide Ribonucleotide Formyltransferase Drug Approval Timeline (2004 - 2024)
The first drug was approved in 2004 (ALIMTA), with the most recent approval in 2024 (AXTLE), spanning 21 years.
The continued approvals suggest sustained interest, but saturation may increase regulatory hurdles for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 319 (141 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Glycinamide Ribonucleotide Formyltransferase. A trial counts if an approved drug acting on Glycinamide Ribonucleotide Formyltransferase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.